Physician profile
Stephen R Cherry
NPI 1346217247
$3,299.74
in general payments reported to CMS, 2019-2025
30 companies · $824 in 2025
The $824 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.06 · 2021: $119 · 2022: $751 · 2023: $565 · 2024: $1,028 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,417.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,416.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $405.66 | 2023-2025 | Farxiga, Andexxa |
| Merck Sharp & Dohme LLC | $327.16 | 2021-2025 | Verquvo, Capvaxive |
| Philips North America LLC | $319.40 | 2024-2025 | Ambulatory Monitoring & Diagnostics Undivided, (5091) Amb Mon & Diag Und, (Cm9) Amb Mon & Diag Und |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.55 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $281.19 | 2022-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $270.01 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $237.19 | 2022-2024 | Xarelto |
| Pfizer INC. | $196.55 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.96 | 2022-2024 | |
| Abbott Laboratories | $91.76 | 2024-2025 | Cardiomems, Mitraclip, Gallant |
| Impulse Dynamics (USA) INC. | $79.29 | 2021-2022 | |
| Novo Nordisk INC | $67.83 | 2024-2025 | Wegovy |
| Irhythm Technologies, INC. | $64.34 | 2024 | Zio Monitor, Zio Xt Patch |
| Edwards Lifesciences Corporation | $63.68 | 2024-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Abiomed | $63.64 | 2024 | Impella |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $58.73 | 2021-2025 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $58.05 | 2021-2025 | Lifevest |
| Bridgebio Pharma, INC. | $42.70 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $38.62 | 2024 | |
| Inari Medical, INC. | $37.24 | 2022 | |
| Medtronic, INC. | $33.42 | 2022 | |
| Daiichi Sankyo INC. | $26.47 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $22.41 | 2024 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals, Ltd. | $21.12 | 2023 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $18.54 | 2025 | Onpattro |
| Boston Scientific Corporation | $17.65 | 2025 | Cds - Mct/Cem Monitoring |
| Vital Connect, INC | $17.16 | 2025 | Vitalpatch Rtm |
| Alexion Pharmaceuticals, INC. | $16.91 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.44 | 2023 | |
| Vivaquant INC, Dba Rhythm Express | $7.07 | 2025 | Rhythm Express |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.